Project Portfolio

Description: Demonstrating penetration of gepotidacin in tonsillar and prostate tissues.

Mode of Action (MoA): Topoisomerase type II inhibitor.

Description: Molecule targeting mycobacterial cholesterol cycle.

Mode of Action (MoA): Cholesterol catabolism.

Description: Compound targeting Mycobacterium tuberculosis tryptophan synthase, an enzyme that catalyses the final two steps in tryptophan biosynthesis.

Mode of Action (MoA): M. tuberculosis tryptophan synthase.

Description: Compounds targeting energy metabolism.

Mode of Action (MoA): Electron chain transport.

Description: Compound targeting lysine transfer RNA synthase (Rv3598c), which is an essential gene as assessed by transposon mutagenesis.

Mode of Action (MoA): Lysine transfer RNA synthase.

Description: Potent in vitro inhibitory and bactericidal activity against Mycobacterium tuberculosis.

Mode of Action (MoA): Mycobacterial membrane protein Large 3 (Mmpl3)

Description: Natural product analogs active against Mycobacterium tuberculosis.

Mode of Action: Unknown.

Description: Derivative of piperazinobenzothiazinone that acts as an anti-mycobacterial compound.

Mode of Action: Targets and covalently inhibits the enzyme Decaprenyl-phosphoryl-ribose 2'-epimerase (DprE1).

Description: Small molecule oxaborole.

Mode of Action (MoA): Inhibits leucyl tRNA synthetase (LeuRS)

Description: Targets cholesterol cycle in Mycobacterium tuberculosis.

Mode of Action (MoA): Cholesterol catabolism.

Description: Small molecule compound that leads to the depletion of ATP in three mycobacterial species, M. tuberculosis, M. leprae, and M. ulcerans.

Mode of Action (MoA): Inhibits the mycobacterial cytochrome bc1 complex in the cellular respiration pathway.

Description: A novel class of small-molecule antibiotics shown to inhibit new targets within the M. tuberculosis mycolic acid biosynthesis pathway.

Mode of Action (MoA): Covalently inhibits the acyl transferase domain of Mtb Pks13, a polyketide synthase involved in mycolic acid biosynthesis via a novel mode of inhibition.

Description: A novel class of small-molecule antibiotics shown to inhibit new targets within the M. tuberculosis mycolic acid biosynthesis pathway.

Mode of Action (MoA): Covalently inhibits the acyl transferase domain of Mtb Pks13, a polyketide synthase involved in mycolic acid biosynthesis via a novel mode of inhibition.

Description: A novel class of small-molecule antibiotics that targets several Mtb biosynthesis pathways.

Mode of Action (MoA): Inhibits FadD32, a key enzyme at the interface between the fatty acid synthase and polyketide synthase biosynthetic pathways and is involved in mycolic acid biosynthesis.

Description: A novel class of small-molecule antibiotics that targets several Mtb biosynthesis pathways.

Mode of Action (MoA): Inhibits FadD32, a key enzyme at the interface between the fatty acid synthase and polyketide synthase biosynthetic pathways and is involved in mycolic acid biosynthesis.

Description: Gepotidacin is a first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by a novel mechanism of action and binding site by inhibiting two different Type II topoisomerase enzymes. Thanks to positive PhIII results for other indications (uUTI & gonorrhoea), gepotidacin is investigated by GNA NOW for its suitability to treat severe enteric infections in low- and middle-income countries.

Mode of Action (MoA): Topoisomerase type II inhibitor

Description: Lead optimisation program on BC1 inhibitors.

Mode of Action (MoA): Cytochrome bc1 complex in the cellular respiration pathway.

Description: H2L medChem for novel menaquinone biosynthesis inhibitors.

Mode of Action (MoA): Inhibits menG, a product of which catalyses methylation of demethylmenaquinone.

Description: Novel long-acting injectable formulation of bedaquiline for Tb preventive therapy.

Mode of Action (MoA): ATPase.

Description: Novel para-Aminosalicylic acid (PAS) analogues.

Mode of Action (MoA): Dihydrofolate reductase (DHFR).

Description: Exploring known host-directed therapies for TB treatment.

Mode of Action(MoA): Various.

Description: Exploring known host-directed therapies for TB treatment.

Mode of Action (MoA): Various.

Description: BV500 program results from BioVersys' proprietary Ansamycin Chemistry platform. The compounds are designed to circumvent intrinsic resistance mechanisms in M. abscessus, while maintaining a broad anti-NTM spectrum of activity

Mode of Action (MoA): Inhibition of bacterial RNA polymerase

Description: Boosts ethionamide efficacy and lowers the dose with small molecule transcriptional modulators to overcome multi-drug resistant tuberculosis infections.

Mode of Action (MoA): Bacterial transcriptional regulation.

Description: A first-in-class investigational antitubercular agent is being developed to treat tuberculosis as part of a future combination regimen.

Mode of Action (MoA):  Suppresses protein synthesis in Mycobacterium tuberculosis by inhibiting the enzyme leucyl t-RNA synthetase (LeuRS).

Description: A first-in-class investigational antitubercular agent is being developed to treat tuberculosis as part of a future combination regimen.

Mode of Action (MoA): Inhibits an essential enzyme for cell wall synthesis in Mycobacterium tuberculosis.

Description: A newly discovered molecule with a new mechanism of action that has potent antituberculosis activity and a favourable safety profile.

Mode of Action (MoA): Inhibits an essential enzyme for Mycobacterium tuberculosis to synthesise key components of its cell wall.

Description: Delpazolid has in vitro activity against Gram-positive bacteria, including Mycobacterium tuberculosis.

Mode of Action (MoA): Inhibits protein synthesis and mRNA translation.

Description: Boosts ethionamide efficacy and lowers the dose with small-molecule transcriptional modulators to overcome multidrug-resistant tuberculosis infections.

Mode of Action (MoA): Bacterial transcriptional regulation.